

BioProcessing Asia 2018

Call for Abstracts

BioProcessing Asia 2018 is now open for the submission of abstracts for oral and poster presentations. This Announcement provides further details of the Programme and the conference topics. For a full description see www.bioprocessingasia.net

REGISTRATION OPENS 26 MARCH, 2018

This conference follows in the footsteps of the two previous highly successful BPA Conferences in 2014 and 2016 in addressing important issues facing the development of a dynamic, vibrant bioprocessing industry in the Asian region. Six half-day Oral Sessions and an interactive Poster Session will provide conference participants with the latest innovations in bioprocessing and direct access to key international opinion leaders in the field.

The rapidly changing demographics in Asia generate an increasing demand for all types of affordable biopharmaceutical products from prevention to treatment. To a large extent, the ability to satisfy patient needs will rely on the ability of the Asian biopharmaceutical industry to research, develop and manufacture safe and efficacious products. For this, a dynamic and innovative R&D culture is required in concert with the development of high yielding, reliable, reproducible and sustainable processes.

The *Scientific Advisory Committee* and *Session Chairs* welcome abstracts on all topics of the conference which focus on bioprocessing developments that enable improved and sustainable biosimilars, vaccines, blood plasma products and novel therapies.

Register now for BioProcessing Asia. We look forward to your participation!

John Curling
Conference Chair

Neil Goss
Conference Co-chair

Günter Jagschies
Conference Co-chair

Mats Gruvegård
Conference Co-chair

Programme

OPENING KEYNOTE ADDRESS

Monday 12 November

“Innovation and sustainable growth of biosimilars” The Keynote Lecture will be delivered by *Ashok Kumar*, President, Center for Research & Development, IPCA, India.

SCIENTIFIC PROGRAMME

Tuesday 13 November

Session 1: Diseases, Treatments and the Future of Biopharmaceuticals

Rolf G Werner, Professor of Industrial Biotechnology, University of Tübingen, Tübingen, Germany

Arindam Bose, Independent Biotechnology & Bioprocessing Consultant, AbiologicsB, LLC, USA

Access to affordable approaches for the management of diabetes, where the number of patients is increasing rapidly is a particularly pressing challenge throughout Asia. Immune-oncology holds the potential for cancers to become manageable diseases. Advanced strategies using cell and gene therapies or antibody-like drugs with much enhanced potency are needed in developing economies undergoing rapid change of their disease burden from infectious to mainly non-communicable disease. Vaccines but also other preventive measures will play an important role in the prophylaxis and containment of known and emerging diseases. This session is inviting review presentations on topics outlined above and other aspects shaping the future of healthcare in Asia.

Session 2: Innovation and Implementation of Creative Technologies in Drug Development

Dorothee Ambrosius, Head of CMC Strategy Biologicals, Boehringer Ingelheim, Germany

Pranhitha Reddy, President, Gene to BLA Consulting, USA

This session will focus on the innovative technologies from all areas of drug development including protein engineering, process engineering, formulation and delivery for biosimilars, biobetters, new molecular modalities such as ADCs, and bispecific antibodies, or cell and gene therapies. We invite presentations on disruptive technologies and process innovations that improve safety, efficacy and delivery of drugs to patients highlighting innovations while addressing sustainability and cost to patients in Asia. We encourage case studies to illustrate creative solutions and regulatory strategies for successful implementation into practice in GMP.

Wednesday 14 November

Session 3: The Recent Regulatory Environment in Asia

Ineui Lee, Professor, University of Kobe, Japan

Swapnil Ballal, Senior Director Quality Assurance, Biologics, Dr Reddy's Laboratories, India

We invite presentations on changes in the regulation of biotherapeutics globally as well as on specific regulatory trends in Asian region. We would focus on changes being adopted by various health authorities allowing such treatments to reach patients faster. Discussions on trans-national approaches to biopharmaceutical product regulation in Asia would be of great value in this session. Presentations on the development of relevant analytical tools for supporting regulatory requirements and for assurance of quality control are also invited. Innovations that impact the Asian regulatory environment will be especially highlighted.

Session 4: Integrated Approaches for Vaccine Design and Manufacturing

Linda Hwee-Lin Lua, Professor & Protein Expression Facility Director, University of Queensland, Australia

Subhash Kapre, CEO, Inventprise, USA

Engineering vaccines to elicit an effective immune response, for rapid response to emerging pathogens, and to make vaccines cheaply, will require integrated approaches in vaccine design and manufacturing. This session will cover the landmark developments in the vaccine industry and highlight strategies such as platform technologies, novel delivery systems, cold-chain free thermostability formulation, and bioprocessing trends. Of special interest are vaccines to target infectious diseases prevalent in Asia, addressing the vaccine manufacturing and economics challenges faced in this region.

POSTER SESSION

Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology and Coordinator, DBT Center of Excellence for Biopharmaceutical Technology, India

Nihal Tuğcu, Executive Director, Downstream Process Development and Engineering for Biologics, Merck & Co. USA

The Poster Session at BPA 2018 is a central interactive feature allowing participants to discuss detailed results with the poster presenters and other colleagues. A limited number of posters will be selected by the Poster Chairs for short oral presentations. A Best Poster Award will be presented at the close of the conference.

Full details of the poster formats are available on the conference website.

Thursday 15 November

Session 5: Plasma Product Biotechnology: the Changing Environment

Jan M Bult, Plasma Protein Therapeutics Association, USA
Geoffrey Pot, Shire, Belgium

This session will investigate the current and future plasma derived products landscape and will highlight developments in Asia. We also invite contributions looking into the cellular production of plasma proteins, not least to see how new modalities will impact the traditional economics of plasma fractionation. We welcome a discussion of product labelling as a new dimension in many areas such as personalized medicine, but also helpful to prevent counterfeiting. Another focus will be on the experiences in Asia when it comes to plasma fractionation plant development, plant expansion and specific challenges in the plasma products manufacturing landscape in China.

Session 6: Evaluating and Implementing Disruptive Manufacturing Strategies

Suzanne Farid, Professor of Bioprocess Systems Engineering, Co-Director of the Future Targeted Healthcare Manufacturing Hub, University College London, UK

Aaron Goerke, Director/Head, Manufacturing Sciences and Technology, Hoffman-La Roche Ltd., Singapore

This session will discuss strategies for successful implementation of disruptive approaches to manufacturing and facility design, focusing on the business case, challenges and key learnings. We encourage contributions that cover the technical, economic as well as the operational and cultural aspects of implementation of disruptive strategies. Contributions that present industrially-relevant case studies applied across the biotherapeutic spectrum from antibodies through to cell and gene therapies are especially encouraged.

Abstract Submission and Registration

SUBMIT AN ABSTRACT

Abstracts for oral and poster presentations must be submitted through the website. If you have not previously entered a profile on the BPA website please go to **Sign Up** and create one. You can then proceed to **Submit Abstract**. Simply follow the instructions on the abstract page.

Please note that abstracts for oral and poster presentation should be of a high scientific standard, data rich and will be made available to the Session Chairs for review. If you wish to contact a session chair send an email to sac@bioprocessingasia.net where your message will be forwarded appropriately.

The Scientific Advisory Committee and the Session Chairs are responsible for recommending abstracts for presentation. The final choice, ensuring a balanced programme will be made by the Organizing Committee. You will be notified of the acceptance status and session for your presentation in July 2018.

REGISTER FOR BPA 2018

If you have not previously entered a profile on the BPA website please go to **Sign Up** and create one. You can then proceed to **Registration**. Simply follow the instructions on the registration page.

Your registration will not be complete until you have paid the registration fee. Once you have completed the registration information you will be directed to a secure Credit Card payment page.

Fee structure*	Until 2 nd September	From 3 rd September
Academic attendees	US\$ 850	US\$ 1050
All non-Academic attendees	US\$ 1200	US\$ 1500

*You may be eligible for a discount, for example, as an invited academic speaker in which case you will be notified accordingly.

TIMETABLE 2018

26	March	Call for Abstracts Registration Opens
1	June	Last date for Oral Abstracts
1	October	Last date for Poster Abstracts
12-15	November	Conference – BioProcessing Asia 2018



The Conference will be held at the Langkawi International Convention Centre, a world class meeting venue built for the ASEAN Summit Retreat in 2015. The LICC is located just 30 minutes from the Langkawi International airport and 10 minutes from downtown Kuah. The Convention Centre is associated with the Westin Langkawi Hotel.

The organizers have negotiated a reduced rate for registrants of the BPA Conference. There are a number of hotel options within short distances of the LICC for those wishing to make alternative arrangements.

Attendees are asked to book hotel accommodation directly with the Westin Langkawi or other nearby hotels listed on the Conference website.

Further Information

- Further information and regular updates are available on the conference website **www.bioprocessingasia.net**.
- Further information about the conference venue is available on the Langkawi International Convention Centre website at **www.langkawiconvention.com**.
- More information on the adjacent and recommended hotel is available at **www.westinlangkawi.com**.



Join the Bioprocessing Asia LinkedIn group through the website to follow BPA 2018 updates.

SPONSORSHIP

Sponsorship opportunities are open to the biopharmaceutical, vaccine and blood plasma industries and industry organizations.

GE Healthcare Life Sciences has a long-standing history of supporting non-commercial, not-for-profit conferences and is the Principal Sponsor of the BPA Series.



BioProcessing Asia is proud to announce its Conference Partner the "Recovery of Biological Products Conference Series".



**Recovery of
Biological Products**
Conference Series

ORGANIZING COMMITTEE & CONFERENCE INFORMATION

John Curling (Chair), JCC AB, Sweden	john@consultcurling.se
Neil Goss NHG Consulting, Australia	NHGconsulting@bigpond.com
Mats Gruvegård GE Healthcare, Sweden	Mats.Gruvegard@ge.com
Günter Jagschies GE Healthcare, Germany	Guenter.Jagschies@ge.com
Conference Secretariat	info@bioprocessingasia.net

BioProcessing Asia is a biopharmaceutical science and technology focused Conference Series registered in Sweden as a non-profit Association.
Organization no: 802503-6792.